(Total Views: 750)
Posted On: 10/28/2024 10:39:19 PM
Post# of 148870
Maybe: GSK/Pfizer ipo's our non-hiv indications.
Roll us into a new company.
100% of your holdings.
Retaining 15-20 targeted indications.
New company has a survival pipeline.
Kick-off with the Oncology & Inflammation.
Dr. J CEO for 1st few years.
Dr. Lataillade new Chairman.
Later replacing Dr. J @ CEO.
Liscense Agreements all other indications to companies interested as combo with LL.
Tiered payments & etc., to our new company from any of those 3rd party deals.
An Exchange application approval, can take 6 months.
The .02 cents positive cash flow, was the start of quarterly positive cash flow requirements, for listing.
Few more positive quarters & exchange listing approved.
ViiV buys our HIV for a few billion cash.
Dispersed 100% to shareholders.
As a 1 time, Special Dividend.
I do not think Dr. Lataillade goes back to ViiV.
Dr. Sacha joins ViiV in some capacity.
One way or another, we're on a historical path forward.
Roll us into a new company.
100% of your holdings.
Retaining 15-20 targeted indications.
New company has a survival pipeline.
Kick-off with the Oncology & Inflammation.
Dr. J CEO for 1st few years.
Dr. Lataillade new Chairman.
Later replacing Dr. J @ CEO.
Liscense Agreements all other indications to companies interested as combo with LL.
Tiered payments & etc., to our new company from any of those 3rd party deals.
An Exchange application approval, can take 6 months.
The .02 cents positive cash flow, was the start of quarterly positive cash flow requirements, for listing.
Few more positive quarters & exchange listing approved.
ViiV buys our HIV for a few billion cash.
Dispersed 100% to shareholders.
As a 1 time, Special Dividend.
I do not think Dr. Lataillade goes back to ViiV.
Dr. Sacha joins ViiV in some capacity.
One way or another, we're on a historical path forward.
(3)
(0)Scroll down for more posts ▼
